Corbus Pharma (NASDAQ: CRBP) reported Q3 EPS of ($0.06), $0.02 better than the analyst estimate of ($0.08).

Expected Near-Term Milestones

• Continue to screen and enroll patients in both the Phase 2 studies in CF and in systemic sclerosis to remain on track for top-line safety and efficacy results by the end of 2016;
• Continue to collaborate with the University of Pennsylvania School of Medicine on the Phase 2 dermatomyositis study, which is expected to be completed during the first half of 2017;
• File for an EU Investigational Medicinal Products authorization for Resunab with the European Medicines Agency in the fourth quarter of 2015; and
• Conduct additional mechanism of action studies with Resunab in relevant pre-clinical models.

For earnings history and earnings-related data on Corbus Pharma (CRBP) click here.